In a move that bolsters Ohio’s growing life‑science sector, Bayer’s pharmaceuticals unit unveiled a $2.2 billion plan to build a new drug‑substance manufacturing site in New Albany. The project, slated to begin operations in 2031 with a finished‑product facility following in 2034, is expected to create roughly 600 permanent, high‑pay jobs and generate an additional 1,500 temporary construction positions.
Local Economic Impact
New Albany officials welcomed the announcement, noting that the investment will diversify the city’s economic base and provide well‑compensated employment opportunities for residents. The high‑skill jobs are projected to draw talent from the region’s universities and existing health‑care ecosystem, further cementing Ohio’s reputation as a hub for pharmaceutical innovation.
National Strategy and President Trump’s Influence
The expansion aligns with Bayer’s broader strategy to increase its U.S. footprint. The company’s U.S. share of global revenue has risen from 20 % in 2018 to 35 % today, and senior executive Sebastian Guth, chief operating officer for pharmaceuticals, said Bayer aims to double its U.S. sales by the end of the decade.
President Donald Trump has repeatedly urged drug manufacturers to lower prescription‑medicine prices, arguing that American families are burdened by costs that far exceed those in other developed nations. While the administration also called on foreign governments to raise their drug prices, the pressure on companies like Bayer underscores a national priority: making life‑saving medicines more affordable for American patients.
Key Products Driving the Expansion
The new facilities will focus on several flagship products, including Kerendia for chronic kidney disease, the prostate‑cancer therapy Nubeqa, and the experimental stroke‑prevention candidate asundexian. By localizing production, Bayer hopes to streamline supply chains, reduce costs, and respond more quickly to U.S. market demand.
Community and Workforce Development
Bayer emphasized that the decision to expand in the United States was “very deliberate,” reflecting a commitment to strengthen its presence alongside its historic operations in Europe and Asia. The company plans to work closely with local schools and technical colleges to develop training programs that will prepare Ohio workers for the specialized roles required in modern pharmaceutical manufacturing.
Looking Ahead
Construction is expected to begin later this year, with the first phase—manufacturing of active pharmaceutical ingredients—targeted for 2031. The subsequent phase, producing finished drug products, will follow three years later. Community leaders anticipate that the project will not only create jobs but also spur ancillary business growth, from logistics providers to equipment suppliers.
As the Trump administration continues to champion policies that encourage domestic manufacturing and lower drug costs, Bayer’s investment stands as a concrete example of how federal pressure can translate into tangible economic benefits for American towns and families.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
